product

product

Brains Bioceutical to provide EU-GMP CBD API for Brazils first medical approved cannabis product


https://www.prfire.com/

Brains Bioceutical Corp (“BRAINS” or the “Company”)(Vancouver, Canada), a global leader in pharmaceutical, wellness and veterinary cannabidiol (CBD) based Active Pharmaceutical Ingredient (API) production, is proud to announce its landmark accomplishment to bring Brazil’s first registered medical cannabis product under the new regulations that ANVISA put in place in December of 2019, Brains EU-GMP CBD API to the Brazilian market.

“Our partners in Brazil are a global leader in pharmaceutical production and clinical trials. I’m very proud of this historic moment, wherein we have combined our strengths to create the first registered product under the new regime. The standard we have set for the purity of our CBD is second to none. The team of world-renowned scientists and executives at Brains, continue to achieve landmark milestones with a relentless pursuit of historic firsts in the CBD industry. We look forward to monetizing and capitalizing on the resulting market opportunities that this launch will propel us towards. We now have registered CBD product in the epicenter of the European continent within the UK, and supply the CBD material to our South American partner for achieving the first registered cannabis product under the new ANVIA regulations in Brazil.” said Rick Brar, Chairman and CEO of Brains Bioceutical Corp.

Brains South American partner is a leader in the global pharmaceutical industry. Producing approximately 11.5 billion therapeutic doses per year, and has more than 4,200 employees. The company has one of the largest portfolios of generic drugs in Brazil, and supplies both South American and global markets. Since the recent announcement in December 2019, this is the first registered cannabis product under the special category created by ANVISA. We will be able to export Brains EU-GMP CBD API from the UK for our partner in Brazil to formulate their products to be sold in pharmacies and distributors in Brazil and potentially expand that to the rest of South America as the marketplace expands. All of our partners formulations adhere to the highest quality for manufacturing and testing with a view to making it the safest product available in the region. Under the terms of the agreement, Brains will provide its EU-GMP, CBD API to be used in the registered cannabis products.

“Now more than ever, it is important that patients have access to products that do not compromise on safety and quality. We believe that these products are bringing forward the highest quality product into South America. The Brains industry leading regulatory team was able to introduce the first cannabinoid based specials products in the UK and the first to supply our EU-GMP API ingredient to our partner in Brazil. Brains CBD is one of the few natural, plant-based API ingredients available anywhere on the planet. This team will successfully lead Brains to another first later this year, when we spearhead the reshaping of the CBD industry in the UK by taking the same approach for our Novel Foods application,” added Gurdeep Bains, President of Brains.

Since 2014, Brains subsidiary, BSPG Laboratories, has been a leader in clinical stage, natural source, cannabinoid manufacturing located in Sandwich, Kent, United Kingdom. Brains presently has Medicines and Healthcare Products Regulatory Agency’s (MHRA) approval to manufacture an approved pharmaceutical grade ingredient (API) for the global pharmaceutical industry. Having shipped over 100 kilos to Brazil over the past year, Brains has been providing patients in Brazil with reliable access for over 2 years.

About Brains Bioceutical Corp
Brains Bioceutical Corp is a leader in GMP – certified production of naturally sourced active pharmaceutical ingredients (APIs) for the pharmaceutical and nutraceutical industries. Brains Bioceutical is one of the only natural plant-based cannabinoid active pharmaceutical ingredient (API) manufacturers in commercial production today and is involved in academic and clinical trials across the globe.

Brains Bioceutical Corp. Senior Management Team is made up of a rare hybrid of pharmaceutical and consumer goods executives-having held C-suite and other senior positions with companies such as GW Pharma, Merck, Seattle Seahawks, Golden State Warriors, Danone, Earthbound Farms, International Herbs, Cascadia Specialties and The Royal British Navy. This experience allows Brains to execute at a hyper-efficient level in the pharma and wellness categories.

Brains’ wholly owned subsidiary in the UK, BSPG Laboratories is one of only nine companies that has the commercial capability and EudraGMDP certification to produce CBD API, and is only one of four worldwide to source a natural plant based cannabidiol. Brains is currently manufacturing a line of phytocannabinoid THC-free CBD API products.

MHRA Registered API: Inspected and Registered with the MHRA (Medicines and Healthcare Products Regulatory Agency).

API Certificate Number: UK API 48727

SOURCE: http://www.in.gov.br/web/dou/-/resolucao-re-n-1.186-de-20-de-abril-de-2020-253341253

For further information, please contact:
Calvin Rasode, Director of Marketing
Telephone: 1-855-927-2476
Email: calvin@brainsbio.com
Website: www.brainsbio.com

CAUTIONARY STATEMENT:
This news release contains forward looking statements or forward-looking information (“forward-looking statements”) within the meaning of securities laws. Often, but not always, forward looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. All statements, other than statements of historical fact, in this news release are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. Risks, uncertainties and other factors involved with forward-looking statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, there can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

 

Source link

ADF Solutions Announces New Product Versions


ADF Solutions Releases New Digital Forensic Software to Power Field Investigations
Triage digital evidence with a single license for smartphones, tablets, and computers

Bethesda, Maryland: ADF Solutions, the leading provider of automated forensic software for investigators and lab examiners, today announced new software versions for Digital Evidence InvestigatorⓇ, Triage-InvestigatorⓇ, Triage-G2Ⓡ, and Mobile Device InvestigatorⓇ software.

Customers who bundle Mobile Device InvestigatorⓇ with any of ADF’s traditional computer forensic tools can perform digital investigations with a single license for smartphones, tablets, and computers as part of Digital Evidence InvestigatorⓇ PRO, Triage-InvestigatorⓇ PRO and Triage-G2Ⓡ PRO.

Raphael Bousquet, CTO of ADF Solutions, was delighted with the updates in this new software version: “In this software release, we continue to focus on finding as much data as possible in our advanced logical acquisition of mobile devices and can locate new artifacts and even recover deleted artifacts. We also added the ability to search for keywords at the last minute during an on-scene scan which was our most requested feature.”

The new versions of ADF digital forensic software feature:

● Simple multi-workstation deployment with a single configuration file
● Improved artifact capture (Android application usage, Instagram for iOS, Grindr for iOS)
● Automatically encrypt backup to collect protected data (MDI: iOS devices)
● Recover deleted records from apps using the SQLite database
● Enter keywords just before a live/boot scan
● Prepare a Collection Key without Search Profiles to select Captures just before a scan (DEI & Triage-G2Ⓡ)
● Prepare a Collection Key with preconfigured or custom Search Profiles (DEI & Triage-G2Ⓡ)

“In an era where time is critical in solving cases, ADF is focused on providing law enforcement with the digital forensic tools they need to start investigations quickly on-scene”, stated Bret Peters, CEO of ADF Solutions. “I am proud of the work our team has done incorporating new features to empower digital first responders dealing with wide varieties of digital investigations.”

Qualified professionals can request a free trial of ADF forensic software at www.tryadf.com.

About ADF Solutions, Inc. ADF Solutions is the global leader in automated digital forensic software for digital investigations. ADF tools streamline digital investigations, reduce forensic backlogs, and provide digital evidence results and intel from iOS and Android smartphones and tablets, as well as computers, external drives, drive images, and other media storage (USB flash drives, memory cards, etc.) devices. Rosoka multilingual entity extraction capabilities are included in Triage-G2® and Triage-G2® PRO and can be purchased as an add-on to Mobile Device InvestigatorⓇ, Digital Evidence Investigator®, Triage-Investigator® or any of ADF’s PRO tools.

Source link

Clinithink Unveils New Brand, Website and Product Suite for 2020


Clinithink, a leading manufacturer of award winning AI solutions for Healthcare and Life Science, has unveiled their much anticipated new brand, website and product suite today.

The newly redesigned logo represents the company’s first brand refresh since being founded in 2009 and, whilst it remains strikingly simple and brilliantly bold, the logo also includes new features that cleverly reflect the company’s dynamic CLiX technology.

Three orange dots pay homage to the previous logo, a flowing connection between ‘t’ and ‘h’ represent the flow of data that CLiX enables, and an orange baseline accent grounds the logo for added strength and gravitas.

The logo concept also sits neatly with Clinithink’s pledge to ‘join the dots’ within every clinical story to inform healthcare’s biggest decisions. And, beyond the logo itself, unique and vibrant imagery, clean architectural design, and a range of bespoke icons, fonts and colourways are all launched today on the company’s website and social media platforms.

“We are so excited about the launch of our new logo, branding strategy and website” said Nicola Grace, SVP Marketing for Clinithink. “We have been working hard to modernise and refresh the look and feel of our company, in line with the dynamic approach we take to the continuous innovation of our technology, and we really wanted one to speak for the other”.

With the renamed product suite too, Clinithink are more accurately reflecting their position as a forward thinking company that offers leading edge approaches to delivering deeper, faster and more accurate data insights – insights that are saving time, money and lives for their users. CLiX is the AI technology at the core of all Clinithink’s five solutions:

CLiX accelerate – AI for patient matching and identification
CLiX focus – AI for phenotyping & rare disease diagnosis
CLiX revenue – AI for healthcare claims management
CLiX unlock – AI for healthcare data analytics
CLiX vision – AI for patient data insights

Chris Tackaberry, CEO of Clinithink, explains: “This new brand launch brings to an end a year of strategic repositioning for us. With a variety of new use cases for our Clinical Natural Language Processing solution we have been able to reach new global markets, new audiences and new partners, and we are delighted that we now have a superb brand style that can really work alongside our best in class solutions. The timing for rebrand seems just perfect.”

For further information about any of the Clinithink products or services, for a closer look at the new brand, or for any other press or PR enquiries, please contact:
Marketing@clinithink.com
Clinithink, New Kings Beam House, 22 Upper Ground, London SE1 9PD, UK
Tel UK: +44 (0) 292 125 0190
Tel US: +1 978 296 5275
www.clinithink.com

Source link

GPI forecasts healthcare product price potential using advanced analytics


Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices for new products by blending its market-leading database of market access information, GPI pulse¬TM, with a framework that maps payer value perception and behavior.

The framework allows pricing teams to use data to anticipate payer response for early clinical stage drugs – typically an involved and uncertain process. GPI has validated the method in the UK and France and is expanding it across countries captured by GPI pulse. GPI’s framework uses multi-criteria decision analysis and published value frameworks. It is built on GPI’s deep domain knowledge, access to data and rigorous approach to developing and testing new analytics.

“The concept of value in healthcare is key to pricing,” said GPI’s founder and CEO, Preeti Patel, “yet there is little global standardization. We’ve quantified global HTA assessment factors and value drivers into a framework that allows teams to understand the variation in value perception across markets and impact on price.”

GPI has a growing footprint in pricing and market access analytics. GPI pulse TM is a revolutionary platform that captures real-time global price data and reimbursement decisions across 90+ markets at a product and indication level. It supports a wide range of innovative analytical tools, insight generation and P&MA data architecture.

GPI’s customers include price, access and commercial teams within biopharma, who utilize GPI’s data and analytical capabilities to better understand pricing scenarios at an early stage and support market access planning and strategy across the product lifecycle.

About GPI
Global Pricing Innovations (GPI) is a market leader in business intelligence, analytics and innovative solutions for the life science industry. GPI delivers integrated insights, technology solutions and strategy development that make a measurable difference to price, access & commercial teams within biopharma. Our combination of innovative technology platforms, data, and analytical expertise enable industry to drive sustainable price and access strategies and agile infrastructure. GPI’s cultural values are centered on promoting the ambitions of inspiring and talented individuals so together we can make a difference to the life sciences industry. We value collaboration, innovation, openness and authenticity, and work as ‘one team’ with our clients.

As a global company, GPI has operating units and service partners throughout the world. GPI  is a privately held company headquartered in London, UK.

Source link